Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

Blood

Volumn 106, Issue 13, 2005, Pages 4050-4053

  Rajkumar, S Vincent ^a   Hayman, Suzanne R ^b   Lacy, Martha Q ^b   Dispenzieri, Angela ^b   Geyer, Susan M ^b   Kabat, Brian ^b   Zeldenrust, Steven R ^b   Kumar, Shaji ^b   Greipp, Philip R ^b   Fonseca, Rafael ^b   Lust, John A ^b   Russell, Stephen J ^b   Kyle, Robert A ^b   Witzig, Thomas E ^b   Gertz, Morie A ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; M PROTEIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AGITATION; ANEMIA; ANXIETY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON PERFORATION; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MUSCLE WEAKNESS; MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RASH; STOMATITIS; THROMBOCYTOPENIA; TIME SERIES ANALYSIS;

EID: 27744492561     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2817     Document Type: Article

References (22)

1. Kyle RA, Rajkumar SV. Plasma cell disorders. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, PA: W. B. Saunders; 2004;1184-1195.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
6. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
7. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875-887.
8. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-890.
9. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
10. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma [abstract]. Blood. 1999;94(suppl 1):604a. Abstract 2686.
11. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826-831.
12. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
13. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21:4444-4454.
14. Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2004;104:63a. Abstract 205.
15. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
16. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
17. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (mm) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001:775a. Abstract 3226.
18. Richardson P, Jagannath S, Schlossman R, et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) [abstract]. Blood. 2003;102:235a. Abstract 825.
19. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
20. Dimopoulos M, Weber D, Chen C, et al. Evaluating oral lenalidomide (Revlimid-) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract]. Haematologica. 2005;90(suppl 2):160. Abstract 0402.
21. Baz R, Marchant K, Yiannaki EO, et al. Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM) [abstract]. Blood. 2004;104:658a. Abstract 2397.
22. Hansen KE, Kramm HL, Boh D, et al. Risk factors for thrombosis and the beneficial effect of aspirin in patients with antiphospholipid antibodies (aPL) [abstract]. Blood. 2004;104:83a. Abstract 279.